Biosimilars Tidal Wave May Well Create A $10 Bill. Opportunity By 2015 For Indian Companies
This article was originally published in The Pink Sheet Daily
Once the U.S. has regulatory clarity, expected later this year, biologics in development by Indian companies can be valued.
You may also be interested in...
MUMBAI - India's top generic drug maker, Cipla, is speeding up its entry into biosimilars with the newly named Biomab, an equal stake joint venture with an undisclosed Chinese company
BEIJING - Flush with cash from expanding earnings, leading Chinese biotech outfit 3SBio is scanning the globe for promising in-licensing deals to complement its in-house drug development pipeline and is exploring the potential to one day enter the biosimilars markets in the United States and the European Union
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.